Amphetamine vs Methylphenidate for ADHD
For children and adolescents (ages 6-17), methylphenidate should be the preferred first-line stimulant, while for adults, amphetamines demonstrate superior efficacy and should be the first choice. This recommendation is based on the most comprehensive network meta-analysis showing age-specific differences in comparative effectiveness 1.
Age-Specific First-Line Recommendations
Children and Adolescents (6-17 years)
- Start with methylphenidate as the preferred stimulant 1
- Initial dose: 5 mg twice daily (before breakfast and lunch) 2
- Titrate by 5-10 mg weekly based on response 3, 2
- Maximum dose: 60 mg/day 2
Rationale: While both medications are effective, methylphenidate shows a more favorable benefit-risk profile in pediatric populations. The 2018 Lancet network meta-analysis of 10,068 children found methylphenidate superior to placebo with clinician ratings (SMD -0.78) and teacher ratings (SMD -0.82), with better tolerability than amphetamines in this age group 1.
Adults (18+ years)
- Start with amphetamines as the preferred stimulant 1
- Dose range: 12-26 mg/day (optimal net clinical benefit at 18-20 mg/day) 4
- Maximum dose varies by formulation
Rationale: Amphetamines demonstrate significantly greater efficacy in adults (SMD -0.79) compared to methylphenidate (SMD -0.49) 1. The 2026 dose-response analysis confirmed amphetamines achieve higher maximal net clinical benefit in adults, even after accounting for adverse event-related discontinuation 4.
Comparative Efficacy
Direct Comparison Data
Head-to-head comparisons favor amphetamines over methylphenidate in both age groups for symptom reduction:
- Children/adolescents: SMD difference of -0.24 to -0.46 favoring amphetamines 1
- Adults: SMD difference of -0.29 to -0.94 favoring amphetamines 1
- A 2010 meta-analysis found amphetamines moderately more efficacious than methylphenidate across all ages, with effect sizes remaining significant after controlling for study design 5
However, the clinical significance of this difference must be weighed against tolerability, particularly in children where methylphenidate's safety profile is more favorable.
Optimal Dosing Ranges
Methylphenidate
- Children/adolescents: Efficacy plateaus at approximately 45 mg/day 4, 6
- Adults: Efficacy continues increasing without clear plateau (limited data at higher doses) 6
- Therapeutic blood concentration: 7.2-11.3 ng/mL (IQR) or 1.1-16.6 ng/mL (mean±SD) 7
Amphetamines (d-amphetamine)
- Children/adolescents: Efficacy plateaus at approximately 25 mg/day 4, 6
- Adults: Efficacy plateaus above 50 mg/day 6
- Therapeutic blood concentration: 18.4-32.5 ng/mL (IQR) or 16.6-47.1 ng/mL (mean±SD) 7
Tolerability and Safety Differences
Discontinuation Due to Adverse Events
Amphetamines show higher discontinuation rates:
- Children/adolescents: OR 2.30 vs placebo 1
- Adults: OR 3.26 vs placebo 1
- Risk increases above 25 mg/day in children and 50 mg/day in adults 6
Methylphenidate shows better tolerability in children:
- Children/adolescents: No significant difference from placebo 1
- Adults: OR 2.39 vs placebo 1
- Risk increases above 50 mg/day in adults 6
Weight Effects
Amphetamines cause greater weight loss, particularly in the first 3 months:
- Mean weight loss at 3 months: -1.44 kg (amphetamine) vs -0.31 kg (methylphenidate), p=0.005 8
- This is a critical consideration for underweight children or those with growth concerns
Common Adverse Effects (Both Medications)
Per FDA labeling 2:
- Tachycardia and palpitations
- Insomnia and anxiety
- Decreased appetite
- Headache
- Abdominal pain
Guideline-Based Treatment Algorithm
Step 1: Pre-Treatment Assessment 3, 2
Screen for contraindications:
- Cardiac disease: Obtain careful history, family history of sudden death/ventricular arrhythmia, physical exam
- Psychiatric comorbidities: Screen for anxiety, depression, bipolar disorder, psychosis
- Tics/Tourette's syndrome: Assess family history and clinical evaluation
- Glaucoma: Evaluate patients with significant hyperopia
- MAOI use: Contraindicated within 14 days
Step 2: Age-Based First-Line Selection
Step 3: Titration Protocol 3, 2
- Start low and increase weekly
- Monitor with validated rating scales (e.g., IOWA Conners for school-based assessment)
- Titrate to maximum benefit with tolerable side effects
- Do not exceed doses where efficacy plateaus: 45 mg/day for methylphenidate and 25 mg/day for amphetamines in children 4, 6
Step 4: Switching Medications
Switch from first-line to alternative stimulant if:
- Inadequate response after reaching optimal dose range
- Intolerable side effects
- Specific concerns (e.g., excessive weight loss with amphetamines)
Persistence data: At 12 months, 68% remained on methylphenidate vs 56% on amphetamines (not statistically significant, p=0.15), suggesting comparable real-world acceptability 8.
Critical Pitfalls to Avoid
Therapeutic inertia: Do not accept suboptimal response without titrating to effective doses within the plateau range 6
Uncritical dose escalation: Avoid exceeding doses where efficacy plateaus, as harms increase without additional benefit 4, 6
Ignoring age-specific differences: The superior efficacy of amphetamines in adults does not translate to a better benefit-risk profile in children 1
Inadequate monitoring: Both medications require monitoring of:
Missing cardiac screening: Both medications carry risks in patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias 2
Abuse Potential and Storage
Both medications are Schedule II controlled substances with high abuse potential 2. Before prescribing:
- Assess each patient's risk for abuse, misuse, and addiction
- Educate patients and families about proper storage (preferably locked) and disposal
- Monitor throughout treatment for signs of diversion or substance use disorder
- Recognize that misuse can result in overdose and death, particularly with unapproved routes (snorting, injection)
Monitoring Requirements
Initial Phase (First 3 Months)
- Weekly symptom ratings during titration 3
- Vital signs at each visit
- Weight monitoring (especially with amphetamines) 8